Roche Holding AG (RHHVF)
OTCMKTS
· Delayed Price · Currency is USD
325.75
-3.66 (-1.11%)
Jun 5, 2025, 3:59 PM EDT
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
$666,883
Profits / Employee
$88,465
Market Cap
262.14B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 103,249 | -356 | -0.34% |
Dec 31, 2023 | 103,605 | -8 | -0.01% |
Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
Dec 31, 2021 | 100,920 | -545 | -0.54% |
Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 3,116 |
Tian'an Technology Group | 8 |
Elite Pharmaceuticals | 64 |
CytoDyn | 9 |
Glass House Brands | 374 |
Northwest Biotherapeutics | 25 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Roche Holding AG News
- 1 day ago - Roche gets EU nod for Evrysdi's expanded label in spinal muscular atrophy - Seeking Alpha
- 2 days ago - Roche's Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA) - GlobeNewsWire
- 2 days ago - Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study - Benzinga
- 3 days ago - Roche's Tecentriq With Lurbinectedin Increases Survival to Small-Cell Lung Cancer, Study Says - WSJ
- 3 days ago - Roche's Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer - GlobeNewsWire
- 3 days ago - Genentech's Tecentriq Combined with Lurbinectedin Shows Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer - Business Wire
- 5 days ago - New Data Show Genentech's Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer - Benzinga
- 5 days ago - New data show Roche's Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer - GlobeNewsWire